$PTN
PALATIN TECHNOLOGIES INC Stock $ptn

$ptn Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000165495424012498 Filed on September 30, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2024
Revenue	$0.00	$350.0K	$4.490M
YoY Change	-100.0%	-80.11%	-7.49%
Cost Of Revenue		$0.00	$97.64K
YoY Change		-100.0%	-76.75%
Gross Profit		$350.0K	$4.392M
YoY Change		-78.92%	-1.07%
Gross Profit Margin		100.0%	97.83%
Selling, General & Admin	$2.021M	$4.004M	$12.27M
YoY Change	-36.85%	-21.03%	-19.76%
% of Gross Profit		1143.94%	279.34%
Research & Development	$5.744M	$4.672M	$22.40M
YoY Change	14.54%	-36.95%	-1.02%
% of Gross Profit		1334.82%	509.97%
Depreciation & Amortization	$80.79K	$81.96K	$339.1K
YoY Change	-10.23%	2.45%	16.92%
% of Gross Profit		23.42%	7.72%
Operating Expenses	$7.765M	$8.676M	$26.99M
YoY Change	-5.48%	-30.48%	-27.68%
Operating Profit	-$7.765M	-$8.326M	-$22.50M
YoY Change	27.1%	-23.05%	-30.69%
Interest Expense	$5.940K	$91.64K	$17.11K
YoY Change	-45.41%	-8.36%	-14.49%
% of Operating Profit
Other Income/Expense, Net	-$58.96K	$0.00	$696.9K
YoY Change	-126.74%		187.98%
Pretax Income	-$7.824M	-$8.250M	-$29.74M
YoY Change	32.83%	-22.97%	-7.7%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$7.824M	-$8.250M	-$29.74M
YoY Change	32.87%	-22.97%	7.97%
Net Earnings / Revenue		-2357.27%	-662.26%
Basic Earnings Per Share	-$0.39		-$2.02
Diluted Earnings Per Share	-$0.39	-$0.49	-$2.02
COMMON SHARES
Basic Shares Outstanding	19.55M shares	16.14M shares	14.70M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2024 Q2	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.384M	$9.527M	$9.527M
YoY Change	-56.65%	-13.39%	-13.39%
Cash & Equivalents	$2.384M	$9.527M	$9.527M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$228.4K	$242.3K	$242.3K
YoY Change	-82.43%	-87.25%	-87.25%
Inventory		$0.00	$0.00
Prepaid Expenses
Receivables		$0.00	$0.00
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$2.613M	$9.770M	$9.770M
YoY Change	-73.36%	-40.14%	-40.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$307.6K	$388.4K	$915.7K
YoY Change	-48.53%	-43.3%	-42.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$56.92K	$56.92K	$56.92K
YoY Change	0.0%	0.0%	-43.08%
Total Long-Term Assets	$802.6K	$972.6K	$972.6K
YoY Change	-44.34%	-39.89%	-39.21%
TOTAL ASSETS
Total Short-Term Assets	$2.613M	$9.770M	$9.770M
Total Long-Term Assets	$802.6K	$972.6K	$972.6K
Total Assets	$3.415M	$10.74M	$10.74M
YoY Change	-69.64%	-40.12%	-39.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.949M	$4.102M	$4.102M
YoY Change	73.99%	-4.68%	-4.61%
Accrued Expenses	$4.573M	$4.185M	$4.566M
YoY Change	-36.06%	-35.72%	-33.83%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$18.53K	$46.01K	$46.01K
YoY Change	-81.47%	-53.99%	-53.99%
Total Short-Term Liabilities	$9.862M	$9.658M	$9.658M
YoY Change	-27.54%	-36.18%	-36.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.239M	$0.00	$1.196M
YoY Change	-38.88%	-100.0%	-54.0%
Total Long-Term Liabilities	$1.239M	$0.00	$1.196M
YoY Change	-38.88%	-100.0%	-54.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.862M	$9.658M	$9.658M
Total Long-Term Liabilities	$1.239M	$0.00	$1.196M
Total Liabilities	$11.10M	$10.85M	$10.85M
YoY Change	-31.21%	-39.04%	-39.02%
SHAREHOLDERS EQUITY
Retained Earnings	-$449.6M	-$441.8M
YoY Change	6.69%	6.31%
Common Stock	$195.5K	$179.3K
YoY Change	63.63%	53.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.686M	-$111.5K	-$111.5K
YoY Change
Total Liabilities & Shareholders Equity	$3.415M	$10.74M	$10.74M
YoY Change	-69.64%	-40.12%	-39.99%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2024
OPERATING ACTIVITIES
Net Income	-$7.824M	-$8.250M	-$29.74M
YoY Change	32.87%	-22.97%	7.97%
Depreciation, Depletion And Amortization	$80.79K	$81.96K	$339.1K
YoY Change	-10.23%	2.45%	16.92%
Cash From Operating Activities	-$7.016M	-$6.472M	-$31.46M
YoY Change	18.79%	-32.65%	10.71%
INVESTING ACTIVITIES
Capital Expenditures		$4.910K	$42.53K
YoY Change		-90.18%	-90.2%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$12.49M
YoY Change	-100.0%	-100.0%	-517.82%
Cash From Investing Activities	$0.00	-$4.920K	$12.45M
YoY Change	-100.0%	-99.84%	-463.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$14.67M
YoY Change			44.59%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$127.0K	5.991M	$20.55M
YoY Change	-128.28%	493.14%	107.64%
NET CHANGE
Cash From Operating Activities	-$7.016M	-6.472M	-$31.46M
Cash From Investing Activities	$0.00	-4.920K	$12.45M
Cash From Financing Activities	-$127.0K	5.991M	$20.55M
Net Change In Cash	-$7.143M	-486.7K	$1.538M
YoY Change	189.83%	-95.82%	-107.01%
FREE CASH FLOW
Cash From Operating Activities	-$7.016M	-$6.472M	-$31.46M
Capital Expenditures		$4.910K	$42.53K
Free Cash Flow		-$6.477M	-$31.50M
YoY Change		-32.95%	9.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2915760	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	0	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	526000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-32458883	usd
CY2023	ptn	Product Revenue Net ProductRevenueNet	4850678	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	26986211	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	37312561	usd
CY2024	us-gaap	Interest Expense InterestExpense	17114	usd
CY2023	us-gaap	Interest Expense InterestExpense	20013	usd
CY2024Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2992890	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	46014	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1850544	usd
CY2023Q2	ptn	Contingently Redeemable Warrants ContingentlyRedeemableWarrants	263400	usd
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024	us-gaap	Cost Of Revenue CostOfRevenue	97637	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	418470	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22400372	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22630577	usd
CY2024	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12270046	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15290836	usd
CY2024	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	7781844	usd
CY2023	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2024	ptn	Gain Loss On Purchase Commitment GainLossOnPurchaseCommitment	0	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-22496121	usd
CY2024	us-gaap	Investment Income Net InvestmentIncomeNet	376843	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	691981	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	59753	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-429971	usd
CY2023	us-gaap	Other Expenses OtherExpenses	1115765	usd
CY2024	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-6962562	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	4620911	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3747143	usd
CY2024	us-gaap	Income Loss From Subsidiaries Before Tax IncomeLossFromSubsidiariesBeforeTax	-29736113	usd
CY2023	us-gaap	Income Loss From Subsidiaries Before Tax IncomeLossFromSubsidiariesBeforeTax	-28711740	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4674999	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-29736113	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-24036741	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-24036741	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	339075	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	288331	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	371339	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	1872698	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1674337	usd
CY2024	ptn	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	6962562	usd
CY2023	ptn	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	-4620911	usd
CY2024	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-7781844	usd
CY2023	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0	usd
CY2024	ptn	Gain Loss On Purchase Commitment GainLossOnPurchaseCommitment	0	usd
CY2023	ptn	Gain Loss On Purchase Commitment GainLossOnPurchaseCommitment	-1027322	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2915760	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1135740	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	35173	usd
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1154355	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	418471	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-201598	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1109541	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2367651	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-364157	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-354051	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-371122	usd
CY2024	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-3463797	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-2042516	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29271346	usd
CY2024	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2992890	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
CY2024	ptn	Proceeds From Sale Of Business ProceedsFromSaleOfBusiness	9500000	usd
CY2023	ptn	Proceeds From Sale Of Business ProceedsFromSaleOfBusiness	0	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	42526	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	433927	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12450364	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3426817	usd
CY2024	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	56401	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	146062	usd
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14666042	usd
CY2024	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	106392	usd
CY2024	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6045642	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	78	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20548891	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10748591	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1537814	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-21949572	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7989582	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9527396	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7989582	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	17114	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	20013	usd
CY2024	ptn	Conversion Of Liabilities Classified As Warrants ConversionOfLiabilitiesClassifiedAsWarrants	11423203	usd
CY2023	ptn	Conversion Of Liabilities Classified As Warrants ConversionOfLiabilitiesClassifiedAsWarrants	0	usd
CY2024	ptn	Conversion Of Liability Classified Warrants Upon Warrant Exercise ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise	2389903	usd
CY2023	ptn	Conversion Of Liability Classified Warrants Upon Warrant Exercise ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise	0	usd
CY2023	ptn	Offering Expenses OfferingExpenses	1115765	usd
CY2023	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	852345	usd
CY2023	us-gaap	Proceeds From Hedge Financing Activities ProceedsFromHedgeFinancingActivities	852345	usd
CY2023Q2	ptn	Money Market Accounts And Treasury Bills MoneyMarketAccountsAndTreasuryBills	5789218	usd
CY2024Q2	ptn	Vyleesi Contractual Advances VyleesiContractualAdvances	0	usd
CY2023Q2	ptn	Vyleesi Contractual Advances VyleesiContractualAdvances	816750	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	526000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	0	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	526000	usd
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0000911216
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11656714	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17926640	shares
CY2024	ptn	Equity Fees Shares EquityFeesShares	0	shares
CY2023	ptn	Equity Fees Shares EquityFeesShares	0	shares
CY2023	ptn	Equity Expenses Shares EquityExpensesShares	0	shares
CY2024	ptn	Equity Expenses Shares EquityExpensesShares	0	shares
CY2024	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Beginning Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance	1550600	shares
CY2024	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Ending Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance	0	shares
CY2024	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Expired Outstanding Number Ending Balance01 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01	10972	shares
CY2023	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Expired Outstanding Number Ending Balance01 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01	51232	shares
CY2023	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Ending Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance	8.27
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q4	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	121584	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	382541	usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-15543
CY2024	dei	Entity Registrant Name EntityRegistrantName	PALATIN TECHNOLOGIES, INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-4078884
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	4B Cedar Brook Drive
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Cranbury
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08512
CY2024	dei	City Area Code CityAreaCode	609
CY2024	dei	Local Phone Number LocalPhoneNumber	495‑2200
CY2024	dei	Security12b Title Security12bTitle	Common Stock, par value $.01 per share
CY2024	dei	Trading Symbol TradingSymbol	PTN
CY2024	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	55737667	usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19548167	shares
CY2024	dei	Auditor Name AuditorName	KPMG LLP
CY2024	dei	Auditor Location AuditorLocation	Philadelphia, Pennsylvania
CY2024Q2	ptn	Contingently Redeemable Warrants ContingentlyRedeemableWarrants	0	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024	ptn	Product Revenue Net ProductRevenueNet	4490090	usd
CY2024	ptn	License And Contract LicenseAndContract	0	usd
CY2023	ptn	License And Contract LicenseAndContract	3000	usd
CY2024	us-gaap	Revenues Revenues	4490090	usd
CY2023	us-gaap	Revenues Revenues	4853678	usd
CY2023	ptn	Gain Loss On Purchase Commitment GainLossOnPurchaseCommitment	-1027322	usd
CY2024	us-gaap	Other Expenses OtherExpenses	696912	usd
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7239992	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.02
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.21
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14697096	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10890159	shares
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16267875	usd
CY2023	ptn	Stock Based Compensation Amount StockBasedCompensationAmount	1674337	usd
CY2023	ptn	Withholding Taxes Related To Restricted Stock Units Amount WithholdingTaxesRelatedToRestrictedStockUnitsAmount	-146062	usd
CY2023	ptn	Redemption Of Convertible Series B Series C Preferred Stock Amount RedemptionOfConvertibleSeriesBSeriesCPreferredStockAmount	0	usd
CY2023	ptn	Sale Of Common Stock And Warrants Net Of Costs Amount SaleOfCommonStockAndWarrantsNetOfCostsAmount	1199389	usd
CY2023	ptn	Conversion Of Liability Classified Warrants ConversionOfLiabilityClassifiedWarrants	3324653	usd
CY2023	ptn	Warrant Exercises Amount WarrantExercisesAmount	78	usd
CY2023	ptn	Reverse Stock Split Fractional Shares Amount ReverseStockSplitFractionalSharesAmount	0	usd
CY2023	ptn	Reclassification Of Contingently Redeemable Warrants ReclassificationOfContingentlyRedeemableWarrants	-263400	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-24036741	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-1979871	usd
CY2024	ptn	Stock Based Compensation Amount StockBasedCompensationAmount	1872698	usd
CY2024	ptn	Withholding Taxes Related To Restricted Stock Units Amount WithholdingTaxesRelatedToRestrictedStockUnitsAmount	-56401	usd
CY2024	ptn	Sale Of Common Stock Net Of Costs Amount SaleOfCommonStockNetOfCostsAmount	9663475	usd
CY2024	ptn	Conversion Of Liability Classified Warrants ConversionOfLiabilityClassifiedWarrants	11423203	usd
CY2024	ptn	Conversion Of Liability Classified Warrants Upon Warrant Exercise Amount ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount	2389903	usd
CY2024	ptn	Warrant Exercises Amount WarrantExercisesAmount	6048209	usd
CY2024	ptn	Shares Held In Abeyance Amount SharesHeldInAbeyanceAmount	0	usd
CY2024	ptn	Reclassification Of Contingently Redeemable Warrants ReclassificationOfContingentlyRedeemableWarrants	263400	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-29736113	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-111497	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-29736113	usd
CY2024	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	348780	usd
CY2024	ptn	Unrealized Foreign Currency Transaction Gain Loss UnrealizedForeignCurrencyTransactionGainLoss	59753	usd
CY2023	ptn	Unrealized Foreign Currency Transaction Gain Loss UnrealizedForeignCurrencyTransactionGainLoss	-429971	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1218846	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31461441	usd
CY2023	ptn	Purchase Of Marketable Securities PurchaseOfMarketableSecurities	2992890	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10995497	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	100922	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29939154	usd
CY2024	ptn	Description Of Sales Based Payments DescriptionOfSalesBasedPayments	The Company may receive contingent, sales-based milestone payments of up to $159,000,000 on sales of Vyleesi by Cosette Pharmaceuticals, Inc. (“Cosette”) and its licensees
CY2024	us-gaap	Servicing Liability At Fair Value Other Changes In Fair Value ServicingLiabilityAtFairValueOtherChangesInFairValue	4620911	usd
CY2023	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	356003	shares
CY2024	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	7781844	usd
CY2017Q3	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	7500000	usd
CY2024Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	9089113	usd
CY2023Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	2808598	usd
CY2023Q2	ptn	Cash Equivalents Treasury Bill At Carrying Value CashEquivalentsTreasuryBillAtCarryingValue	2980620	usd
CY2023Q2	ptn	Marketable Securities Treasury Bill At Carrying Value MarketableSecuritiesTreasuryBillAtCarryingValue	2992890	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	0	usd
CY2024	ptn	Description Of Office Space DescriptionOfOfficeSpace	The Company has operating leases for office and laboratory space, which expire on June 30, 2025 and October 31, 2026, respectively
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	263859	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	291878	usd
CY2024	us-gaap	Variable Lease Cost VariableLeaseCost	113708	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	114441	usd
CY2024	ptn	Total Operating Lease Cost TotalOperatingLeaseCost	377567	usd
CY2023	ptn	Total Operating Lease Cost TotalOperatingLeaseCost	406319	usd
CY2024	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	106390	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	100922	usd
CY2024	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	5507	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	10975	usd
CY2023	us-gaap	Lease Cost LeaseCost	111897	usd
CY2024	us-gaap	Lease Cost LeaseCost	111897	usd
CY2024	ptn	Weighted Average Remaining Lease Term Years WeightedAverageRemainingLeaseTermYears	1.7
CY2023	ptn	Weighted Average Remaining Lease Term Years WeightedAverageRemainingLeaseTermYears	2.3
CY2024	ptn	Weighted Average Remaining Lease Term Years Finance Lease WeightedAverageRemainingLeaseTermYearsFinanceLease	0.4
CY2023	ptn	Weighted Average Remaining Lease Term Years Finance Lease WeightedAverageRemainingLeaseTermYearsFinanceLease	1.4
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0550	pure
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0550	pure
CY2023Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0529	pure
CY2024Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0529	pure
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	387910	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	406319	usd
CY2024	us-gaap	Operating Lease Expense OperatingLeaseExpense	5507	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	10975	usd
CY2024	us-gaap	Finance Lease Impairment Loss FinanceLeaseImpairmentLoss	106392	usd
CY2023	us-gaap	Finance Lease Impairment Loss FinanceLeaseImpairmentLoss	100922	usd
CY2024	ptn	Total Measurement Of Lease Liabilities TotalMeasurementOfLeaseLiabilities	499809	usd
CY2023	ptn	Total Measurement Of Lease Liabilities TotalMeasurementOfLeaseLiabilities	518216	usd
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	368975	usd
CY2023Q2	ptn	Office Equipment OfficeEquipment	1229300	usd
CY2024Q2	ptn	Office Equipment OfficeEquipment	1229300	usd
CY2024Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1220395	usd
CY2023Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1177868	usd
CY2023Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1196706	usd
CY2024Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1196706	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3646401	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3603874	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3258040	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2918964	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	388361	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	684910	usd
CY2024Q2	ptn	Equipment Under Finance Leases EquipmentUnderFinanceLeases	309791	usd
CY2024Q2	us-gaap	Ground Leases Accumulated Amortization GroundLeasesAccumulatedAmortization	263777	usd
CY2024	us-gaap	Proceeds From Grantors ProceedsFromGrantors	15000000	usd
CY2024	ptn	Voting Of Shares Description VotingOfSharesDescription	The holders of Series C Preferred Stock were entitled to 20,000 votes per share
CY2024Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	6.82
CY2024	ptn	Warrant To Purchase Common Stock WarrantToPurchaseCommonStock	1033491	shares
CY2023	ptn	Warrant To Purchase Common Stock WarrantToPurchaseCommonStock	1033491	shares
CY2022Q4	ptn	Description Of Securities Purchase Agreement DescriptionOfSecuritiesPurchaseAgreement	(i) 1,020,000 shares of the Company’s common stock, (ii) prefunded warrants (the “October 2022 Pre-Funded Warrants”) to purchase up to 798,182 shares of the Company’s common stock, and (iii) common stock warrants (the “October 2022 Common Warrants”) to purchase up to 1,818,182 shares of the Company’s common stock. Each share of common stock was offered with one accompanying October 2022 Common Warrant with a combined offering price of $5.50. Each October 2022 Pre-Funded Warrant was offered with one accompanying October 2022 Common Warrant with a combined offering price of $5.4999
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.83
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.0001
CY2022Q4	ptn	Warrant To Purchase Common Stock WarrantToPurchaseCommonStock	798182	shares
CY2022Q4	us-gaap	Costs And Expenses CostsAndExpenses	9109117	usd
CY2024	ptn	Description Of Commission DescriptionOfCommission	The Company pays Canaccord 3.0% of the gross proceeds as a commission
CY2023	ptn	Equity Gross Proceeds Shares EquityGrossProceedsShares	504034	shares
CY2023	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	1196739	usd
CY2023	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	35902	usd
CY2023	ptn	Equity Expenses Proceeds EquityExpensesProceeds	126800	usd
CY2023	ptn	Equity Net Proceeds Shares EquityNetProceedsShares	504034	shares
CY2023	ptn	Equity Net Proceeds Proceeds EquityNetProceedsProceeds	1034037	usd
CY2023	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Beginning Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance	1163962	shares
CY2023	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Beginning Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance	15.98
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P7Y1M6D
CY2023	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Number Ending Balance73 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73	712310	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.30
CY2023	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Forfeited Outstanding Number Ending Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance	-274440	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	12.00
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	17.45
CY2023	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Ending Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance	1550600	shares
CY2024	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Number Ending Balance73 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73	742800	shares
CY2024	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Forfeited Outstanding Number Ending Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance	-18988	shares
CY2024Q2	ptn	Unvested Performance Based Stock Options Granted To Executive Officers And Other Employees UnvestedPerformanceBasedStockOptionsGrantedToExecutiveOfficersAndOtherEmployees	418945	shares
CY2024Q2	ptn	Unvested Performance Based Stock Options Granted UnvestedPerformanceBasedStockOptionsGranted	88911	shares
CY2021Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	95167	usd
CY2022Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	60566	usd
CY2023Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	238838	usd
CY2024Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	264945	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.043	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.039	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.758	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.656	pure
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2024	ptn	Weighted Average Grant Date Fair Value Per Share WeightedAverageGrantDateFairValuePerShare	0.82
CY2023	ptn	Weighted Average Grant Date Fair Value Per Share WeightedAverageGrantDateFairValuePerShare	0.99
CY2024	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	873633	usd
CY2023	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	794735	usd
CY2024	ptn	Unrecognized Compensation Cost UnrecognizedCompensationCost	1409506	usd
CY2024	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Period Remaining1 NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1	P2M21D
CY2022Q2	ptn	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber	649149	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	517800	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	425750	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	11667	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	3312	shares
CY2023	ptn	Restricted Stock Vested In Period RestrictedStockVestedInPeriod	-84062	shares
CY2023	ptn	Fractional Shares FractionalShares	-4	shares
CY2023Q2	ptn	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instrument Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber	987521	shares
CY2024	us-gaap	Restricted Stock Expense RestrictedStockExpense	839335	usd
CY2023	us-gaap	Restricted Stock Expense RestrictedStockExpense	616182	usd
CY2024Q2	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Veste Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVesteOutstandingNumber	508011	shares
CY2024	ptn	Sale Value Of The Tax Benefits To Unaffiliated SaleValueOfTheTaxBenefitsToUnaffiliated	0.80	pure
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4674999	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	181000000	usd
CY2024Q2	ptn	Federal Rd And Alternative Minimum Tax Credits FederalRDAndAlternativeMinimumTaxCredits	9500000	usd
CY2024	us-gaap	Allowance For Loan And Lease Losses Loans Acquired AllowanceForLoanAndLeaseLossesLoansAcquired	11193000	usd
CY2023	us-gaap	Allowance For Loan And Lease Losses Loans Acquired AllowanceForLoanAndLeaseLossesLoansAcquired	5653000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	40051000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	40073000	usd
CY2024Q2	ptn	Research And Development And Amt Tax Credits ResearchAndDevelopmentAndAmtTaxCredits	9464000	usd
CY2023Q2	ptn	Research And Development And Amt Tax Credits ResearchAndDevelopmentAndAmtTaxCredits	8094000	usd
CY2023Q2	ptn	Basis Difference In Foreign Tax Credits BasisDifferenceInForeignTaxCredits	583000	usd
CY2024Q2	ptn	Basis Difference In Foreign Tax Credits BasisDifferenceInForeignTaxCredits	583000	usd
CY2024Q2	ptn	Basis Differences In Fixed Assets And Other BasisDifferencesInFixedAssetsAndOther	12611000	usd
CY2023Q2	ptn	Basis Differences In Fixed Assets And Other BasisDifferencesInFixedAssetsAndOther	2766000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	62709000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	51516000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	62709000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	51516000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2024	dei	Auditor Firm AuditorFirmId	185

Files In Submission

Name	View Source	Status
0001654954-24-012498-index-headers.html	Edgar Link	pending
0001654954-24-012498-index.html	Edgar Link	pending
0001654954-24-012498.txt	Edgar Link	pending
0001654954-24-012498-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ptn-20240630.xsd	Edgar Link	pending
ptn_10k.htm	Edgar Link	pending
ptn_10kimg30.jpg	Edgar Link	pending
ptn_10kimg31.jpg	Edgar Link	pending
ptn_ex19.htm	Edgar Link	pending
ptn_ex21.htm	Edgar Link	pending
ptn_ex23.htm	Edgar Link	pending
ptn_ex311.htm	Edgar Link	pending
ptn_ex312.htm	Edgar Link	pending
ptn_ex321.htm	Edgar Link	pending
ptn_ex322.htm	Edgar Link	pending
ptn_ex97.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ptn-20240630_cal.xml	Edgar Link	unprocessable
ptn-20240630_def.xml	Edgar Link	unprocessable
ptn-20240630_lab.xml	Edgar Link	unprocessable
ptn-20240630_pre.xml	Edgar Link	unprocessable
ptn_10k_htm.xml	Edgar Link	completed
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTN
PALATIN TECHNOLOGIES INC Stock $ptn

2024 Q3 Form 10-K Financial Statement

#000165495424012498 Filed on September 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTN PALATIN TECHNOLOGIES INC Stock $ptn

2024 Q3 Form 10-K Financial Statement

#000165495424012498 Filed on September 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTN
PALATIN TECHNOLOGIES INC Stock $ptn